Figure 4 | Scientific Reports

Figure 4

From: Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients

Figure 4

Percentage and expression of CD25 by CD3 T lymphocytes of melanoma patients treated with CPIs. Frequency (a) and median fluorescent intensity (MFI) (b) of CD25 were analyzed by flow cytometry in PBMCs within CD3 T cell population of melanoma patients before (T0) and after 3 months (T2) of treatment. Pearson’s correlation analysis between serum CD25 levels (pg/ml) and frequency of CD3+ CD25+ T cells (c), or MFI of CD25 within CD3 T cells (d) was shown. Best overall response according to iRECIST criteria: iPD, progressive disease (n. 7 patients); iSD, stable disease (n. 8 patients); iPR, partial response (n. 8 patients); complete response, iCR (n. 10 patients). (a,b) Data are indicated as mean value ± standard error of the mean (SEM). *p < 0.05 as assessed by Mann–Whitney U test to compare between-group differences.

Back to article page